156 results about "Transforming growth factor" patented technology

The invention provides a mesenchymal stem cell preparation for promoting knee joint repair as well as a preparation method and application thereof, and belongs to the technical field of medicines. The preparation method comprises the following steps: loading transforming growth factor-beta1 and interleukin-6 on chitosan microspheres, then preparing a chitosan-oxidized starch-carboxymethyl-beta-cyclodextrin bracket loaded with sustained release microspheres, loading luteolin and quercetin, carrying out mixed culture with mesenchymal stem cells, adding a traditional Chinese medicine extract, and carrying out freeze-drying to obtain the luteolin-quercetin-modified mesenchymal stem cells. The mesenchymal stem cell preparation for promoting knee joint repair is prepared. The preparation method of the carbon anode plate for fluorine preparation is simple, the generation of polarization of the carbon anode plate is prevented, and the carbon anode plate has the advantages of low porosity, low ash content, high mechanical strength, high volume density, obviously prolonged service life, low resistivity and the like, and has a wide application prospect.

The invention belongs to the technical field of electrochemical sensors, and particularly relates to an in-situ self-amplification nucleic acid-based flexible wound sensor and a preparation method thereof. The sensor comprises a flexible substrate, a gold layer and a nucleic acid sensing layer, the nucleic acid sensing layer comprises a tumor necrosis factor-alpha sensor, an interleukin 6 sensor, a transforming growth factor beta1 sensor, a vascular endothelial growth factor sensor, a temperature sensor, a pH sensor, a reference electrode and a counter electrode; the tumor necrosis factor-alpha sensor, the interleukin 6 sensor, the transforming growth factor beta1 sensor and the vascular endothelial growth factor sensor are all modified with rigid DNA tetrahedrons with hairpin DNA H2 and corresponding hairpin DNA H1. The sensor provided by the invention has antifouling and anti-degradation effects; finally, in-situ nucleic acid amplification on the flexible biosensing interface is realized by virtue of a hydrophilic / hydrophobic confinement effect and an auxiliary nucleic acid pre-fixation strategy, so that the detection sensitivity is improved.

The invention provides an improved blastocyst culture solution as well as a preparation method and application thereof, and relates to the field of embryonic cell in-vitro culture. Based on a formula of a conventional blastocyst culture solution, colony stimulating factor-1 (CSF-1) and a transforming growth factor-alpha (TGF-alpha) are added, and the colony stimulating factor-1 and the transforming growth factor-alpha are dissolved in the conventional culture solution according to the concentration of 0.02-0.06 mmol / L and the concentration of 0.01-0.05 mmol / L; the obtained improved blastocyst culture solution can improve the mulberry embryo formation rate or blastocyst formation rate in in-vitro culture, promote the development of low-quality embryos and improve the mulberry embryo quality or blastocyst quality, and can be used for preparing medicines for promoting embryo implantation or subsequent growth and development.

The invention discloses a liver progenitor organoid culture medium and a culture method, and belongs to the technical field of organoid culture. The culture medium comprises a basic culture medium, Jagged-1, Dexamehysone, TGF (Transforming Growth Factor)-alpha, beta-mercaptoethanol, BMP4 (Bone Morphogenetic Protein 4), FGF2 (Fibroblast Growth Factor 2), specific addition factors Glutamax, HEPES (Hydroxyethyl PES), Nicotinamide, Penicillin and the like. The liver progenitor organoid is constructed by using the liver tissue for the first time, continuous growth and efficient proliferation of human liver progenitor cells in vitro can be promoted under the condition that gene editing is not carried out, meanwhile, the pluripotency of the liver progenitor organoid is maintained, and the consistency of specific marker expression is maintained; and a novel batch model is provided for the evaluation of hepatotoxicity at the present stage. From the long-term view, a foundation is laid for constructing a liver organ model with more advanced various differentiated cells.

This invention belongs to the field of nutritional composition technology, specifically disclosing a composition for promoting brain cognitive development, its preparation method, and its application. The composition for promoting brain cognitive development provided by this invention includes transforming growth factor, casein phosphopeptide, immunoglobulin, and sn-2 DHA, and further specifies that the mass ratio of transforming growth factor, casein phosphopeptide, immunoglobulin, and sn-2 DHA is (0.1~1.4) ng:(40000~160000) mg:(20000~60000) mg:(20000~70000) mg. In this invention, the preferred ratio of transforming growth factor, casein phosphopeptide, immunoglobulin, and sn-2 DHA can achieve the effect of promoting brain cognitive development through a multi-dimensional synergistic mechanism.

The present invention addresses the problem of providing: synovium-derived mesenchymal stem cells that stably exhibit an excellent therapeutic effect on joint diseases; an arthropathy therapeutic agent that contains the synovium-derived mesenchymal stem cells; a method for producing the synovium-derived mesenchymal stem cells; and a method for selecting synovium-derived mesenchymal stem cells for use as an arthropathy therapeutic agent. The present invention provides synovium-derived mesenchymal stem cells that express at least one of a hepatocyte growth factor, a transforming growth factor β-inducing protein, and tumor necrosis factor superfamily 15.

Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGFβ1 with high potency. Related compositions, methods and therapeutic use are also disclosed.

The invention belongs to the field of biological agents, and particularly relates to application of polypeptide HRH and analogues thereof in preparation of drugs for treating pulmonary fibrosis. The amino acid sequence of the polypeptide HRH disclosed by the invention is NH2-His-Arg-His-Thr-Lys-Gln-Arg-His-Thr-Ala-Leu-His-CONH2. An in-vitro experiment proves that the polypeptide HRH can be used for effectively inhibiting pulmonary epithelial cell and fibroblast fibrosis induced by a transforming growth factor and silicosis fibrosis induced by silicon dioxide; in-vivo experiments further prove that the HRH can improve bleomycin-induced pulmonary fibrosis lesion of mice and improve weight loss and death rate of the mice, and meanwhile, the HRH has relatively high safety and no adverse toxic or side effect. The invention also provides an HRH polypeptide analogue which can more effectively inhibit the activation of fibroblasts. The polypeptide HRH prepared by the invention is low in dosage, safe and effective, and provides a potential new medicine for treating pulmonary fibrosis diseases.

The invention belongs to the field of anti-cancer drugs, and particularly relates to a transforming growth factor-beta inhibitor # imgabs0 #. The invention further discloses preparation of the transforming growth factor-beta inhibitor and application of the transforming growth factor-beta inhibitor in preparation of anti-tumor drugs. The inhibitor provided by the invention has excellent transforming growth factor-beta inhibitory activity, and can effectively resist tumors based on the mechanism.

Provided are multi-functional and multi-valent fusion polypeptides comprising an interleukin polypeptide and two or more TGFβ ligand-binding polypeptides. The compositions and methods provided herein are useful in the application of treating and / or preventing pathogenic infections.

The present disclosure relates to endoplasmic reticulum protein HYOU1-binding compounds for inhibiting endoplasmic reticulum-mitochondrial interactions and uses thereof.The features and advantages of the present disclosure may be summarized as follows:(a) The present disclosure provides a compound that can bind to the endoplasmic reticulum protein HYOU1 and inhibit endoplasmic reticulum-mitochondrial interactions increased by oxLDL (oxidized low-density lipoprotein).(b) The present disclosure provides a composition capable of preventing, ameliorating or treating autophagy disorder-related diseases, particularly arteriosclerosis or pulmonary hypertension, which contains the above-described compound as an active ingredient.(c) Since the composition of the present disclosure reduces intracellular lipids by inducing autophagy in atherosclerosis-induced tissues, it can be useful used in the amelioration or treatment of atherosclerosis.(d) Since the composition of the present disclosure reduces smooth muscle cell proliferation by inducing autophagy in smooth muscle cells in which contraction is induced by TGF-β, it can be usefully used in the amelioration or treatment of pulmonary arterial hypertension.

The invention discloses a serum substitute compatible umbilical cord mesenchymal stem cell culture medium additive composition and application thereof. The serum substitute compatible umbilical cord mesenchymal stem cell culture medium additive composition is prepared from the following components in parts by mass: 15 to 25 parts of platelet-derived growth factor-BB; 15 to 25 parts of basic fibroblast growth factors; 8 to 12 parts of transforming growth factor-beta; and 8-12 parts of recombinant human insulin. The serum substitute compatible umbilical cord mesenchymal stem cell culture medium additive composition and the application thereof disclosed by the invention have the following beneficial effects: (1) the proliferation efficiency is remarkably improved; (2) the cell morphology and dryness can be well maintained; and (3) the compliance and the compatibility are good.

The invention relates to the technical field of biology, in particular to a human CD4 and TGF-beta1 / 2 / 3 combined bispecific antibody which at least comprises a first protein functional area, and the first protein functional area comprises a first antigen binding site targeting CD4; and the second protein functional region comprises a second antigen binding site targeting TGF (Transforming Growth Factor)-beta 1 / 2 / 3. The bispecific antibody disclosed by the invention can be well and specifically combined with CD4 and specifically combined to helper T cells; meanwhile, the bispecific antibody can be combined with TGF beta 1, so that Th1 cell mediated cellular immunity is activated, TGF beta 2 and TGF beta 3 are neutralized, and the bispecific antibody has the effect of preparing the medicine for preventing and treating bacterial infectious diseases.

This invention relates to a skin cell dispersion for autologous treatment of skin wounds. Specifically, this invention provides a skin cell dispersion containing skin cells, epidermal growth factor, and transforming growth factor-β1. The skin cell dispersion of this invention exhibits excellent therapeutic effects on skin wounds.

An implant device for an eye disease to be inserted into an eyeball may include: a tube having one end to be inserted into an anterior chamber of the eyeball, the tube including a hollow portion through which aqueous humor is drained; and a matrix coupled to an outer surface of the tube and formed of a material capable of impregnating and releasing a drug. At least a part of the matrix may have a cross-section larger than a diameter of the tube. When the implant device for an eye disease is used, an antifibrotic agent, such as dexamethasone, mitomycin-C (MMC), 5-fluorouracil (5-FU), triamcinolone (TA), an anti-vascular endothelial growth factor (VEGF) inhibitor, or a transforming growth factor-beta-beta (TGF-β) inhibitor may be loaded on the matrix, and the antifibrotic agent may be released to surrounding tissue from the matrix after the implant device is inserted.

This invention provides an organ fibrosis-related micropeptide, OFMP, and its applications. This type of micropeptide, OFMP, is a translational product with endogenous biological activity and stable existence, encoded by an open reading frame (ORF) in a long non-coding RNA. It is the first time that the long non-coding RNA encoding the micropeptide has been found to be significantly related to organ fibrosis and can encode the micropeptide. Synthetic peptides prepared based on the aforementioned OFMP micropeptide show significant inhibitory effects on several key indicators of organ fibrosis, including type I collagen α1 chain gene, α-smooth muscle actin, transforming growth factor β1, and connective tissue growth factor. This indicates that the OFMP micropeptide, the nucleotide sequence (ORF) encoding the micropeptide, and the long non-coding RNA sequence containing the nucleotide sequence have important clinical diagnostic and therapeutic value for organ fibrosis.

The present disclosure provides methods for identifying therapeutic agents for treating ejection fraction preserved heart failure. The method may comprise: contacting a cardiac tissue or cardiac organoid with an effective amount of transforming growth factor-pi and an effective amount of endothelin-1 (ET-1) to induce ejection fraction preserved heart failure in the cardiac tissue; exposing the cardiac tissue or cardiac organoid exhibiting heart failure with preserved ejection fraction to a candidate therapeutic agent; and if the cardiac tissue or cardiac organoid induces a reduction in any one or more of the following characteristics of the cardiac tissue or cardiac organoid if the candidate therapeutic agent induces a reduction in any one or more of the following characteristics of the cardiac tissue or cardiac organoid, if yes, identifying the candidate therapeutic agent as a therapeutic agent for ejection fraction preserved heart failure: passive strain, stiffness, myocardial cell hypertrophy, or fibrosis. In some embodiments, the candidate therapeutic agent identified as a therapeutic agent for treating ejection fraction preserved heart failure induces an increase in contraction kinetics or relaxation kinetics. Additional embodiments of the disclosed methods identify therapeutic agents that induce any combination of the above altered characteristics of cardiac tissue and / or cardiac organoids.

The invention provides an induced pluripotent stem cell culture medium and a culture method of induced pluripotent stem cells. The induced pluripotent stem cell culture medium comprises a basic culture medium, a composite additive A and a composite additive B, the composite additive A comprises 5-30 [mu] g / mL of recombinant human insulin growth factors, 1-5 ng / mL of recombinant human transforming growth factors, 50-200 ng / mL of recombinant human basic fibroblast growth factors, 7-20 [mu] g / mL of sodium selenite, 0.5-2 mg / mL of albumin, 50-70 [mu] g / mL of ascorbic acid and 5-20 [mu] g / mL of transferrin; the composite additive B is prepared from 50 to 300mg / mL of a Stock B solution, 0.5 to 5 percent (v / v) of a non-essential amino acid solution, 50 to 200ng / mL of DL-piperidinecarboxylic acid, 50 to 200mu g / mL of gamma-aminobutyric acid, 0.1 to 1 percent (v / v) of a lipid concentrated solution, 0.5 to 5 percent (v / v) of an L-alanyl-L-glutamine solution and 0.1 to 0.1 percent of mercaptoethanol. The culture medium for the induced pluripotent stem cells provided by the invention can ensure the self-renewal capability of the iPSCs in a long-term passage process; and the genetic stability of the iPSCs cells is optimized according to the genome integrity and pluripotent state.

The invention discloses a method and a pharmaceutical composition for inhibiting tumor growth by combining an mRNA vaccine and a transforming growth factor-beta (TGF-beta) antibody. The medicine composition comprises an mRNA vaccine for coding a tumor specific antigen and a monoclonal antibody for specifically targeting TGF-beta, and tumor specific immune response induced by the mRNA vaccine is combined with the effect of the TGF-beta antibody for relieving tumor microenvironment immunosuppression, so that the killing ability of a body to tumor cells is remarkably enhanced; the compound provided by the invention can effectively inhibit tumor growth and prolong the lifetime of tumor-bearing individuals, has good safety and tolerance, and provides a new effective strategy for tumor treatment.

A treatment composition for inhibiting systemic sclerosis Vimentin mutant protein activity by using an STAT6 inhibitor, which inhibits the expression of an M2 macrophage and a profibrotic T cell which are immunocytes related to systemic sclerosis, and increases the expression of a Treg, and inhibits the expression of TGF-β, Col1a1, and α-SMA which are fibrosis factors related to systemic sclerosis. The presence of a pSTAT6 expression CD8 T cell in a fibrosis tissue has been identified, and that the expression of a pSTAT6 expression CD8 T positive cell is controlled via injection of the STAT6 inhibitor. In an animal model with increased Vimentin-specific disease symptom activity, the STAT6 inhibitor inhibits antigen-specific tissue fibrosis of systemic sclerosis with activated disease symptoms, and that the STAT6 inhibitor inhibits the expression of IL-17 cytokine expression CD8 positive TRM capable of inducing fibrosis and cell inflammation which are systemic sclerosis diseases.

To provide methods for the production of tissue resident memory-like T cells by the combination of hypoxia and TGFβ.SOLUTION: An in vitro method for producing tissue resident memory-like T cells (TRM-like T cells) comprises: (a) obtaining a starting population of T cells; (b) culturing the starting population of T cells in hypoxic conditions or in the presence of a hypoxia-inducing agent to generate early effector cells; and (c) further culturing the early effector cells in the presence of transforming growth factor β1 (TGF-β1) to produce TRM-like T cells.SELECTED DRAWING: None

Provided herein are methods of treating a mitral valve disease in a subject. The method comprises administering to the subject a gene therapy comprising a first nucleic acid encoding soluble transforming growth factor beta receptor 2 (sTGF beta R2) and a second nucleic acid encoding fibroblast growth factor 21 (FGF 21). Also provided are methods of treating a mitral valve disease in a subject comprising administering a gene therapy to the subject in combination with an additional therapeutic agent (e.g., pimobendan).

The invention relates to the technical field of biological medicines, and particularly discloses an application composition of stem cell exosomes in promoting tissue repair, which comprises the stem cell exosomes selected from induced pluripotent stem cells, mesenchymal stem cells, embryonic stem cells, hematopoietic stem cells or neural stem cells and used for promoting tissue repair and cell regeneration, and the stem cell exosomes selected from the induced pluripotent stem cells, the mesenchymal stem cells, the embryonic stem cells, the hematopoietic stem cells and the neural stem cells. The tissue repair promoting factor is selected from an epidermal growth factor, a transforming growth factor beta, a platelet-derived growth factor or a combination thereof, and is used for optimizing cell proliferation, differentiation and wound healing; the biodegradable carrier is selected from hydrogel, lipidosome, polymer micelle, nano particles or natural plant extract; by optimizing the transmission relation between the biodegradable carrier and the stem cell exosome and combining with the cell proliferation model, different doses and delivery modes can be flexibly regulated and controlled, the treatment scheme is further optimized, and the effect of the treatment scheme is accurately predicted. Due to the design, the common problems of unstable effect, long treatment period and the like in the traditional stem cell application are solved.

The present disclosure provides nucleic acids encoding a transforming growth factor inhibitor and IL-12. Also provided herein are nucleic acids encoding the chemokine receptor CXCR3. Additionally described herein are oncolytic viruses comprising the nucleic acids described herein. The use of the compositions described herein in the treatment of cancer is also described.

The invention belongs to the technical field of tissue engineering, and particularly relates to a bio-ink system for osteochondral repair as well as a preparation method and application of the bio-ink system. The system comprises first bio-ink and second bio-ink which are respectively used for simulating cartilage and bone tissue. The first biological ink is prepared from methacrylic acid gelatin, acellular extracellular matrix powder, aldehyde modified natural polysaccharide, a photoinitiator and a transforming growth factor; the second biological ink is prepared from methacrylic acid gelatin, acellular extracellular matrix powder, nano-hydroxyapatite, aldehyde modified natural polysaccharide, a photoinitiator and human bone morphogenetic protein BMP-2. The bio-ink system can guarantee smooth extrusion and interlayer fusion in the printing process; the constructed bionic microenvironment and the affinity effect of the bionic microenvironment on growth factors are suitable for 3D printing construction of the osteochondral integrated bionic scaffold and have good clinical transformation potential.

The invention relates to the field of bone tissue engineering and regenerative medicine, in particular to non-denatured bone protein calcium superfine powder with bone tissue oriented growth and rapid repair effects and a preparation method and application of the non-denatured bone protein calcium superfine powder, and the non-denatured bone protein calcium superfine powder comprises the following components in percentage by weight: 25%-45% of non-denatured type I collagen, 0.005%-0.05% of bone morphogenetic protein-2, 0.001%-0.02% of transforming growth factor-beta1, 0.01%-0.02% of calcium sulfate, 0.01%-0.02% of calcium sulfate, 0.01%-0.02% of calcium The bone tissue repairing agent is prepared from, by weight, 0.001%-0.02% of basic fibroblast growth factors, 20%-40% of ultramicro hydroxyapatite nanoparticles, 5%-15% of chitosan oligosaccharide, 3%-10% of mannitol calcium complex, 2%-8% of sodium hyaluronate, 0.01%-0.1% of vitamin D3, 0.01%-0.1% of vitamin K2, 5%-15% of chondroitin sulfate, 1%-4% of casein phosphopeptides and the balance auxiliary materials, and directional growth and rapid repairing of bone tissue are promoted.

This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, long-term dialysis. For example, prediction of long-term dialysis treatment can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of approximately fourteen Days measuring hyaluronic acid, death receptor 5, and / or transforming growth factor β1 can be used to establish the risk of recovery versus non-recovery in patient's having suffered an acute kidney injury.

The invention discloses an anti-aging composition containing recombinant collagen. The composition comprises the following components: (1) 2-5g of recombinant collagen; (2) 1-2 g of hyaluronic acid; (3) 0.2 to 0.5 g of a collagen degradation product; (4) 0.2 to 0.3 g of an anti-TGF (Transforming Growth Factor)-beta 1 monoclonal antibody; (5) 0.2 to 0.5 g of vitamin C; (6) 0.2 to 0.3 g of vitamin E; (7) 0.5-1 g of a green tea extract; and (8) adding the aqueous solution to 100 g. The anti-aging composition can effectively delay the skin aging process, improve the skin elasticity and reduce generation of wrinkles and fine wrinkles. The composition not only can be used in daily skin care products, but also can be used for treating skin problems caused by aging, such as skin laxity, fine wrinkles and darkness, and has a remarkable market prospect.

An scFv-Fc dimer binds and neutralizes TGFβ1 selectively and with high affinity and avidity. The scFv region may comprise the same VH and VL domains or CDR regions as metelimumab. The unique combination of their smaller size, high selectivity, potency against TGFβ1, and long in vivo half-life makes the scFv-Fc dimers ideal candidates for therapeutic applications.

This invention proposes a method for preparing dental pulp stem cell exosomes and their applications, belonging to the field of exosome technology. Dental pulp stem cells from exfoliated deciduous teeth are seeded into serum-free α-MEM medium containing microparticles, insulin-like growth factor, transforming growth factor-β1, penicillin, and streptomycin for culture. Exosomes are isolated, dispersed in PBS solution, and incubated with microparticles, propylene glycol, and rhodioloside to obtain highly active dental pulp stem cell exosomes. The surface of these exosomes is then modified with shikonin and interferon to obtain dental pulp stem cell exosomes. The dental pulp stem cell exosomes prepared by this invention exhibit good affinity for titanium implant-mediated osteointegration repair materials, demonstrating good anti-inflammatory, immunomodulatory, osteogenic, and damage-reducing effects. Furthermore, the preparation method is simple, yields high output, and operates under mild conditions, showing broad application prospects.